Physician profile
Simo Huang
NPI 1346730066
$5,227.52
in general payments reported to CMS, 2019-2025
23 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $339 · 2021: $1,009 · 2022: $1,213 · 2023: $854 · 2024: $1,167 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.60 |
| Education | $390.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,226.81 | 2020-2024 | Tremfya |
| Janssen Scientific Affairs, LLC | $1,121.63 | 2019-2022 | |
| Abbvie INC. | $528.94 | 2020-2025 | |
| Genzyme Corporation | $373.19 | 2021-2024 | |
| Leo Pharma INC. | $306.99 | 2023-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $267.25 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $174.88 | 2019-2022 | |
| Lilly USA, LLC | $165.79 | 2021-2023 | Taltz |
| Helsinn Therapeutics (U.S.), INC. | $146.33 | 2020-2022 | |
| Ucb, INC. | $145.12 | 2022-2024 | Bimzelx |
| Incyte Corporation | $140.28 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $110.51 | 2021-2025 | Dupixent |
| Journey Medical Corporation | $95.26 | 2024 | |
| Pfizer INC. | $83.80 | 2024 | |
| Dermavant Sciences, INC. | $74.65 | 2024 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Revance Therapeutics, INC. | $48.64 | 2025 | Daxxify |
| Amgen INC. | $35.47 | 2024 | Otezla |
| Springworks Therapeutics, INC. | $32.21 | 2025 | Gomekli |
| Sun Pharmaceutical Industries INC. | $23.66 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.66 | 2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $13.61 | 2023 | |
| Organon LLC | $10.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simo Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.